African Americans (AAs) compared to European Americans (EAs) have poorer stage specific survival from colorectal cancer (CRC), especially among younger patients. We used population-based Surveillance, Epidemiology, and End Results (SEER) registry data to evaluate the impact of race, age on advanced stage CRC survival. We found that younger AAs (vs. EAs) had a significantly higher risk of death which was attenuated in older patients. Introduction: African Americans (AAs) compared with European Americans (EAs) have poorer stage-specific survival from colorectal cancer (CRC). Recent reports have indicated that the racial difference in survival has worsened over time, especially among younger patients. To better characterize this association, we used population-based Surveillance, Epidemiology, and End Results registry data to evaluate the effect of race on stage IV CRC survival in patients aged < 50 and ! 50 years. Patients and Methods: The population included 16,782 patients diagnosed with stage IV colon and rectal adenocarcinoma from January 1, 2004 and December 31, 2011. Cox proportional hazards regression was used to evaluate the association between race and other prognostic factors and the risk of death in each age group. Results: Younger AAs compared with EAs had a greater prevalence of proximal CRC at diagnosis, a factor associated with a significantly greater risk of death in both races. Among patients < 50 years old, AAs had a greater risk of death compared with EAs (hazard ratio, 1.35; 95% confidence interval, 1.20-1.51), which was attenuated in patients ! 50 years of age (hazard ratio, 1.10; 95% confidence interval, 1.04-1.16); P for interaction ¼ .01.
Introduction
African Americans (AAs) compared with European Americans (EAs) have a greater colorectal cancer (CRC) incidence and poorer stage-specific survival. 1, 2 For most Americans, survival has improved significantly during the past 20 years; however, for AAs, the rates have improved more slowly, especially for those with advanced disease stages. 2, 3 Also, younger AAs appear to be more vulnerable to CRC, because the relative difference in survival by race has been more pronounced in younger than in older patients. [4] [5] [6] A primary reason for the improvement in stage IV CRC survival has been the better treatment options available. Since the introduction of combination chemotherapy and biologic agents in 2004, the median survival for stage IV CRC has increased from approximately 10 months in the mid-1990s to 20 months in 2008. 7, 8 In our previous study, 4 we found that the racial disparity in advanced CRC had worsened over time, especially among younger age AAs compared with EAs with a diagnosis of CRC after 2003. One of the reasons for the poorer survival for AAs compared with EAs might be because of the greater prevalence of proximal neoplasia in AAs, [9] [10] [11] [12] [13] [14] which is often associated with worse survival, [15] [16] [17] [18] especially in the context of metastatic disease. A recent investigation has found that treatment with biologic agents appears to be less effective in patients with proximal CRC compared with distal or rectal cancer. 19 In our previous study, we had a limited number of cases < 50 years old and only 2 years of CRC case data after the introduction of the biologic therapies. Therefore, in the present analysis, we took advantage of the population-based Surveillance, Epidemiology, and End Results (SEER) registry data to investigate racial differences in CRC survival in younger (< 50 years) and older (! 50 years) patients with stage IV CRC diagnosed after 2003. Our analysis focused on stage IV cases from 2004 to 2011 for several reasons, including similar standard recommended treatment guidelines, a large relative difference in survival by race in stage IV CRC, and a high proportion of patients dying of CRC, rather than of competing causes. We also investigated whether clinical or pathologic factors at diagnosis (colonic location, histologic type, grade, elevated carcinoembryonic antigen [CEA]) differ by race and help to explain the differences observed in survival.
Patients and Methods

Study Population
The SEER Program of the National Cancer Institute is a population-based data system that collects cancer incidence in 18 regions within the United States. The mortality data reported by SEER are provided by the National Center for Health Statistics. For our analysis, the study population included adults (! 18 years old) with pathologically documented colon and rectal adenocarcinoma in the SEER registry diagnosed from January 1, 2004 to December 31, 2011 with positive follow-up time (> 0 days). SEER codes the cancer stage using the SEER staging criteria, defined as local, regional, or distant disease. We further limited the study population to include only patients who presented with distant disease (equivalent to TNM stage IV), which includes disease detected in the lymph nodes or other distant sites. We used the following additional case selection criteria to further define the study population: single primary tumor only; AA or EA race; tumor histologic type reported as adenocarcinoma not otherwise specified, mucinous adenocarcinoma, or signet ring cell adenocarcinoma; tumor grade reported as well-differentiated, moderately differentiated, poorly differentiated, or undifferentiated (grade I, II, III, or IV, respectively); colonic location proximal (cecum, ascending colon, or hepatic flexure transverse colon); distal (splenic flexure, descending colon, or sigmoid colon); or rectal (rectosigmoid or rectum); and CEA serum level at diagnosis, either normal or elevated. Patients with variable values other than those specified (including missing or unknown values) were excluded from the final analysis set (Figure 1 ).
Statistical Analysis
Statistical analysis was performed using SAS, version 9.4, and R, version 3.1.2. 20 All analyses were performed using data stratified by age at diagnosis (< 50 vs. ! 50 years) and gender, with the primary comparisons within strata being those between EA and AA patients. Univariate associations of demographic and clinical characteristics with race were evaluated using Wilcoxon rank-sum tests for continuous variables and c 2 tests for categorical variables.
Overall survival was calculated as the interval in months from diagnosis of distant stage CRC to death from any cause. The survival times for patients alive as of December 31, 2011 were censored at the end of the follow-up period. Kaplan-Meier methods were used to estimate the median survival time, 5-year survival probabilities, and corresponding 95% confidence intervals (CIs). Comparisons between survival curves were performed using log-rank tests.
The factors' associations with survival were evaluated by fitting Cox proportional hazards (CPH) regression models. Because of the significant interaction between age category and race, we fit separate CPH regression models for the 2 age groups. The P value for interaction for both univariate and multivariable CPH models was 0.01. We first fit univariate CPH models to investigate the unadjusted associations between demographic and clinical characteristics and survival. We then fit multivariable CPH models with the independent variables of age (as a continuous variable), race, and gender (model 1) and, also with the colonic location, tumor grade, histologic type, and CEA elevation status (model 2). Finally, we further stratified by gender and fit all univariate and multivariable CPH models described (with gender removed as an independent variable). The associations were summarized using hazard ratios (HRs) and the corresponding 95% CIs.
Results
The population included 14,182 EA patients (85%) and 2600 AA patients (15%), for 16,782 patients with data available for analysis. Of the 2735 patients aged < 50 years, 82% were EAs and 18% AAs. Of the 14,047 patients aged ! 50, 85% were EAs and 15% AAs. Also, of the 8932 men, 86% were EAs and 14% AAs, and of the 7750 women, 83% were EAs and 17% AAs. Overall, the survival was better for the younger than for the older patients, irrespective of race. Among the AA group, those aged < 50 years had a median survival of 20 months (range, 18-22 months) compared with 13 months (range, 12-14 months) for those aged ! 50 years. Similarly, in the EA group, the median survival for the younger group was 25 months (range, 24-26 months) compared with 14 months (range, 14-15 months) for the older group.
Patients Aged < 50 Years
Overall, 19% of the AA patients with CRC were < 50 years old compared with 16% of the EA patients (Table 1 ). In those aged < 50 years, several pathologic features differed significantly at diagnosis by race. These included tumor location, tumor grade, and CEA level. Specifically, the prevalence of proximal CRC was 17% greater in AA women than in EA women and 9% greater in AA men than in EA men. In contrast, the incidence of rectal cancer was 10% lower in AA women than in EA women and 9% lower in AA men than in EA men. CEA positivity was 6% greater in both AA men and women than in EA men and women. The prevalence of high-grade tumors in AA and EA men was 24% and 33%, respectively. No significant differences were observed in histologic types.
The median survival was lower in AAs than in EAs (Table 2, Figure 2 ). Relative to EA women, AA women had significantly worse survival (18 months vs. 25 months) and lower 5-year survival rates (0.12 vs. 0.18; log-rank P < .0001). For both AA Abbreviations: CEA ¼ carcinoembryonic antigen; NOS ¼ not otherwise specified.
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and EA women, the median survival was lowest for those with proximal neoplasia (Table 2 ). AA women with distal and rectal disease experienced worse survival than EA women (21 vs. 27 months with distal disease; 17 vs. 29 months with rectal disease).
Using stratified Cox regression analysis (Table 3) , AA women had a significantly greater risk of death compared with EA women (HR, 1.48; 95% CI, 1.25-1.75). Adjustment for clinicopathologic covariates slightly attenuated the risk (HR, 1.39; 95% CI, 1.17-1.65). Overall, young AA men experienced worse survival compared with young EA men (log-rank P ¼ .006), with lower median survival Table 2 ). Similar to women, the young men of both races with proximal CRC had the lowest survival. In young men, the greatest difference in survival was observed with rectal cancer when comparing AA and EA men (21 vs. 26 months). Stratified Cox regression analysis revealed that AA men had a greater risk of mortality than EA men (HR, 1.25; 95% CI, 1.06-1.47; Table 3 ), even after adjustment for clinical covariates (HR, 1.29; 95% CI, 1.10-1.52).
Patients Aged ! 50 Years
The personal characteristics and clinical and pathologic features assessed at diagnosis differed by race in those aged ! 50 years ( Table 1 ). The average age at diagnosis was 3 years younger for the AA men and 4 years younger for the AA women compared with EA men and women, respectively. Similar to observations in patients aged < 50 years, the older AA men and women were more likely to have proximal tumors and greater CEA positivity but less likely to have high-grade lesions. Older AA women had a 5% greater prevalence of proximal tumors than did EA women. However, this difference was appreciably lower than the 17% difference observed in the younger cohort.
Overall, the median survival was slightly greater for older EA patients than for AA patients (Table 2, Figure 2) . Most of the racial difference in survival in those aged > 50 years was confined to the men. For example, the median survival did not differ by race in women aged > 50 years (13 months in EA women vs. 14 months in AA women). The 5-year survival probability was only slightly greater in older EA women relative to AA women (0.10 vs. 0.07). Furthermore, the risk of death did not differ significantly by race in older women (HR, 1.03; 95% CI, 0.95-1.11; Table 3 ). Adjustment for the multiple prognostic factors at diagnosis increased the risk by 6% (HR, 1.09; 95% CI, 1.01-1.18). In contrast, the median survival for older AA men was poorer than that for EA men (13 months vs. 16 months). Likewise, the 5-year survival probability was lower for older AA men than for EA men (0.07 vs. 0.10). From the stratified CPH regression models, the univariate analysis revealed a greater risk of death for older AA men than for EA men (HR, 1.18; 95% CI, 1.09-1.27; Table 3 ). Adjustment for covariates led to an increase in this racial difference (HR, 1.24; 95% CI, 1.15-1.34).
Discussion
Our analysis using the population-based SEER registry data revealed poorer stage-specific survival for AA patients than for EA patients, especially for those aged < 50 years. Overall, we observed that CRC was diagnosed in 19% of AA patients who were aged < 50 years compared with 16% of EA patients. Significantly worse survival was observed for AA men in both younger and older age groups; however, the largest racial difference in survival was found for AA women aged < 50 years, who had a 48% greater risk of death than younger EA women. In contrast, survival was poor for all women ! 50 years old. The prevalence of several poor prognostic factors at diagnosis differed by race, age, and gender and appears to explain some of the reasons for the differences in survival when stratified by race and age. AA patients of all ages had a greater prevalence of proximal tumors and higher CEA level compared with EA patients but a lower prevalence of high-grade tumors. Much of the difference in CRC survival by race in younger women appeared to result from the difference in the prevalence of proximal neoplasia at diagnosis. In summary, our findings highlight the importance of considering the patient's age, gender, and colonic location when assessing the differences by race in stage IV CRC outcomes.
CRC is the second leading cause of cancer-related death yet one of the most preventable and treatable cancers when identified in the early stages, with 90% survival at 5 years compared with < 20% for stage IV cases. Despite recommendations by some physician organizations to begin screening earlier in AAs, 21, 22 others have argued that efforts should be directed toward increasing the screening rates in those aged ! 50 years, 23 because of the scarcities of resources and the much greater prevalence of disease in older patients. In the case of the present SEER cohort with stage IV CRC, approximately one sixth of the cases were diagnosed before 50 years of age. Moreover, the average age at diagnosis for the younger patients was 45 years for AA men, 44 years for EA men, and 44 years for both AA and EA women. From a public health perspective, screening younger AAs should be considered, regardless of the underlying etiology, given the poor survival and high prevalence of poor prognostic factors such as a proximal location. 
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The results of the present investigation mirror earlier reports showing that the survival differences were most pronounced by race for younger patients. 4, 5, 24 In our earlier investigation, using the South Carolina Central Cancer Registry data, we explored the associations between race, age, and clinicopathologic features and stage IV CRC survival. The multivariable proportional hazards regression analysis showed that AA patients compared with EA patients had a significantly greater risk of death after controlling for age, gender, year of diagnosis, and first-line chemotherapy use. Just as in the present analysis, we observed a significant interaction between race and age (P ¼ .04) on survival. Among AA patients versus EA patients aged < 50 years, the adjusted HR was 1.34 (95% CI, 1.06-1.71). The magnitude of the HR for patients aged < 50 years was similar to the adjusted HR found in the present study (HR, 1.33; 95% CI, 1.18-1.49). The reason for the greater risk of death in younger patients is clearly complex but was due, at least in part, to the greater prevalence of proximal CRC in younger AA patients compared with younger EA patients ( Table 2 ). Similar to these results, many others [25] [26] [27] [28] [29] have reported a greater prevalence of proximal or advanced proximal neoplasia, especially microsatellite stable CRC in AA patients compared with EA patients. A proximal colonic location outside of the context of microsatellite instability-high CRC has been associated with greater mortality, especially among stage IV CRC patients. 15, 17, 30, 31 Recent evidence has also documented a poorer response to treatment in patients with proximal CRC. 19 The racial difference in survival by race and gender differed in the younger and older patients. As reported, a marked difference was found in the prevalence of proximal CRC in women aged < 50 years (þ17% for AA women) but only a 5% difference by race was found for those aged ! 50 years. The reasons for the racial difference in survival among the younger women are not known but might reflect differences in the hormonal signatures by race. Younger EA women compared with younger AA women have higher estrogen levels, [32] [33] [34] which could contribute to a lower prevalence of proximal neoplasia in younger women. Recently, a large prospective study reported a strong inverse association between endogenous estrogen levels and the risk of CRC, especially for colon cancer compared with rectal cancer. 35 One possibility is that estrogen receptor expression loss results in more aggressive tumor behavior. In a murine model, the loss of estrogen receptor expression in the proximal colon led to crypt fission and reduced wound healing, 36 factors associated with increased tumor prevalence and growth. Moreover, poorer survival has been observed in younger AA women compared with EA women with breast cancer, which might be explained by the greater proportion of poor prognostic ER À breast cancer tumors in AA women. 37 The poorer survival in younger AA women in the present study was similar to what we observed in our previous analysis. 4 Racial differences in initiation and adherence to standard treatment of CRC might contribute to the stage-specific survival differences. AA patients historically have been less likely to receive the standard recommended therapy and to refuse therapy at a greater rate. 38 Although data on systemic therapy use are not available from the SEER data set, the available agents (capecitabine, 5-fluorouracil, the possibility that metastectomy rates might differ by race. To our knowledge, only 1 previous study has evaluated metastectomy rates by race and reported no differences. 42 However, 2 large studies 42, 43 found that AA patients had significantly lower response rates to therapy, which could reduce the likelihood of undergoing resection. The strengths of our study included the study of a large, racially diverse population of patients with advanced-stage CRC with careful characterization of the demographic and pathologic characteristics and vital status. However, we also recognize its limitations. First, we had no data on patient-level factors (eg, comorbid conditions or lifestyle and behaviors) or treatment regimen data, which could have confounded or modified the association between race and CRC survival. These results point to the need for detailed studies identifying the risk factors for poor prognostic signatures and patient-level, clinical, molecular, and treatment-related data to help advance our understanding of the racial disparity in CRC survival.
Conclusion
Using the large population-based SEER data set, we have shown that AA patients with stage IV CRC have greater mortality than EA patients, in particular, those aged < 50 years. These data suggest greater emphasis is needed for CRC screening of younger AA individuals and, further, raise the possibility that national guidelines for CRC screening should be modified, especially for AA women.
Clinical Practice Points
Several previous investigations have detailed a racial disparity in CRC survival, yet the reasons for this remain incompletely understood. The greater rates of death for AA compared with EA patients have persisted despite adjustment for common confounding variables such as gender, age, and socioeconomic status. Our results suggest that the racial difference in survival might be influenced by differences in the prevalence of proximal and rectal CRC at diagnosis, because survival among both AA patients and EA patients with proximal stage IV CRC disease is poor. Future research is needed to understand why AAs develop proximal neoplasia at a younger age; we found a 17% difference in the prevalence of proximal CRCs in younger AA women compared with younger EA women but only a 5% difference by race among women aged ! 50 years. A better understanding of how to improve the treatment response in patients with stage IV proximal CRC is also needed.
